Innate Pharma (IPHA) news

Innate and Sobi announce partnership is now effective following completion of closing conditions

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sobi® have confirmed that their strategic partnership is now effective following the completion of all closing conditions, including necessary anti-trust clearances . Under the terms of the agreement, Sobi has paid Innate Pharma USD 75…

Swedish Orphan Biotriment - Innate eligible for up to $40 mln in near-term development milestones connected to Sezary syndrome

Innate Pharma has made significant progress in its clinical development pipeline for lacutamab, an anti-KIR3DL2 antibody targeting Sézary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma (CTCL). The company is currently preparing for the initiation of the TELLOMAK-3 Phase 3 trial…

Sobi will pay Innate Pharma $75M

Innate Pharma - preliminary data from 76 patients expected by year-end

Innate Pharma - IPH4502 shows favorable safety profile with hematological toxicity to date

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has reported that its investigational Antibody Drug Conjugate (ADC), IPH4502, has demonstrated a favorable safety profile in early clinical trials, with primary observed adverse event . The drug is currently being evaluated in a Phase 1 trial…